Nautilus Q3 Loss Widens to $15.6M; Revenue Tops Estimates at $234K
NAUT has more than doubled off its 52-week low of $0.841 on elevated volume (3.5× avg).
Summary
Nautilus reported a Q3 net loss of $15.636 million, or -$0.12 per share, with operating expenses of $16.947 million, and ended the quarter with $114.3M in cash. Revenue came in at $234 thousand, ahead of the $206.2 thousand IBES estimate — a small beat on a still-tiny base. The loss is the headline number: this is a pre-commercial story, and the cash burn matters more than the top line. The company already told investors in Q2 that its broadscale assay is delayed to early 2027, and it has a $125M ATM program in place to fund the wait. Watch the cash balance and any update on the early-2027 launch timeline.
At the time of this announcement, NAUT was trading at $2.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $310.5M. The 52-week trading range was $0.84 to $4.31. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.